Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Invest New Drugs
Hauptverfasser: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2015
Schlagworte:
Phase II Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://ncbi.nlm.nih.gov/pubmed/26123926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0269-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge